CFO of Aveo to resign seven months after drug failure

The chief financial officer of Aveo Oncology, who helped bring the Cambridge company public in 2010 and has stayed on since the company’s stock crashed this spring following the rejection of its lead drug by U...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.